The CEO of ubiquitous U.K. fast-food retailer Greggs said there was "no doubt" that appetite-suppressing drugs mean customers are now looking for smaller portions, and this is having an impact on the company's profits.

Roisin Currie told BBC News that people are also looking for "protein and fiber," and generally healthier options, adding that the food retailer has been introducing products to make the most of that market.

Greggs, which describes itself as a bakery chain, previously said people's dietary changes, and a “broader health trend” have led it to move away from its best-selling but high-fat pasties, cakes and pastries, with new offerings in 2025 including “Eggs at Greggs” products, including peeled, boiled eggs.

Currie's comments come as the firm reported lackluster profits and a muted forecast for 2026. The company reported revenue of  £1.81 billion ($2.43 billion) in 2023. It said in July 2025 that it plans to expand from 2,600 outlets in the U.K. to 3,000 in the future.

Currie said the firm had "to make sure that we've got some of the snack products that customers are looking for if they are on any of the GLP-1 drugs."

The BBC said several other food retailers have noted that customers appetites are changing as a result of weight loss drugs.

Recently, a ban came in to force across the U.K. banning adverts for junk foods before 9pm, which the government said was to help stem rising rates of obesity.

In the U.S., according to CNBC, a 2024 Cornell University study found that households with at least one GLP-1 user cut their spending on groceries by 5.3% within six months of adoption, with that rate rising to 8.2% among higher-income households.